Zoetis Inc. (NYSE:ZTS) insider Kristin C. Peck sold 10,092 shares of Zoetis stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $49.55, for a total value of $500,058.60. Following the completion of the transaction, the insider now directly owns 22,768 shares of the company’s stock, valued at $1,128,154.40. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Shares of Zoetis Inc. (NYSE:ZTS) opened at 50.18 on Friday. Zoetis Inc. has a 52-week low of $38.26 and a 52-week high of $53.14. The firm has a 50 day moving average price of $50.18 and a 200-day moving average price of $49.58. The company has a market cap of $24.78 billion, a price-to-earnings ratio of 36.18 and a beta of 1.05.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported $0.52 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.46 by $0.06. Zoetis had a return on equity of 72.96% and a net margin of 14.10%. The company had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.22 billion. During the same quarter last year, the business posted $0.50 earnings per share. The firm’s revenue was up 2.2% compared to the same quarter last year. Equities research analysts anticipate that Zoetis Inc. will post $1.94 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Thursday, November 3rd will be given a $0.095 dividend. The ex-dividend date is Tuesday, November 1st. This represents a $0.38 dividend on an annualized basis and a dividend yield of 0.76%. Zoetis’s dividend payout ratio (DPR) is presently 27.54%.

Several large investors have recently modified their holdings of ZTS. Assetmark Inc. increased its stake in shares of Zoetis by 7.5% in the third quarter. Assetmark Inc. now owns 1,930 shares of the company’s stock worth $100,000 after buying an additional 134 shares during the period. NEXT Financial Group Inc increased its stake in shares of Zoetis by 9.5% in the second quarter. NEXT Financial Group Inc now owns 2,136 shares of the company’s stock worth $101,000 after buying an additional 186 shares during the period. Kelly Lawrence W & Associates Inc. CA increased its stake in shares of Zoetis by 113.4% in the second quarter. Kelly Lawrence W & Associates Inc. CA now owns 2,446 shares of the company’s stock worth $116,000 after buying an additional 1,300 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in shares of Zoetis by 22.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,566 shares of the company’s stock worth $121,000 after buying an additional 476 shares during the period. Finally, Glenmede Trust Co. NA increased its stake in shares of Zoetis by 4.4% in the second quarter. Glenmede Trust Co. NA now owns 2,950 shares of the company’s stock worth $139,000 after buying an additional 124 shares during the period. Institutional investors own 94.94% of the company’s stock.

ZTS has been the subject of several analyst reports. Argus lifted their price objective on Zoetis from $54.00 to $58.00 and gave the company a “below average” rating in a report on Friday, September 9th. Jefferies Group reissued a “buy” rating and set a $60.00 price target on shares of Zoetis in a report on Tuesday, August 23rd. Bank of America Corp. assumed coverage on Zoetis in a report on Thursday, September 29th. They set a “buy” rating and a $60.00 price target for the company. Stifel Nicolaus reissued a “buy” rating and set a $58.00 price target on shares of Zoetis in a report on Wednesday, October 12th. Finally, Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $56.00 price target for the company in a report on Monday, November 7th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $55.83.

COPYRIGHT VIOLATION WARNING: “Kristin C. Peck Sells 10,092 Shares of Zoetis Inc. (ZTS) Stock” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2016/11/25/kristin-c-peck-sells-10092-shares-of-zoetis-inc-zts-stock.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

5 Day Chart for NYSE:ZTS

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.